Imaging response during therapy with radium-223 (Ra-223) for castration-resistant prostate cancer (CRPC) with bone metastases (BM): A multicenter analysis.

被引：3
|
作者：
Omlin, Aurelius Gabriel
Daugaard, Gedske
Peer, Avivit
Reichegger, Hermann
Neumann, Avivit
Rosenbaum, Eli
Desax, Marie-Claire
Neiman, Victoria
Petersen, Peter Meidahl
Mueller, Joachim
Cathomas, Richard
Gottfried, Maya
Sarid, David
Gez, Eli
Mermershtain, Wilmosh
Rouvinov, Keren
Mortensen, Jann
Gillessen, Silke
Keizman, Daniel
机构：
[1] Kantonsspital St Gallen, St Gallen, Switzerland
[2] Copenhagen Univ Hosp, Copenhagen, Denmark
[3] Rambam Hlth Care Campus, Haifa, Israel
[4] Cantonal Hosp St Gallen, St Gallen, Switzerland
[5] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[6] Rabin Med Ctr, Dept Oncol, Petah Tiqwa, Israel
[7] Rabin Med Ctr, Davidoff Canc Ctr, Petach-Tikva, Israel
[8] Rigshosp, Dept Oncol, Copenhagen, Denmark
[9] Kantonsspital Chur, Chur, Switzerland
[10] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel
[11] Ichilov Hosp, Sourasky Med Ctr, Tel Aviv, Israel
[12] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel
[13] Soroka Med Ctr, Beer Sheva, Israel
[14] Rigshosp, Nucl Med & PET, Dept Clin Physiol, Copenhagen, Denmark
[15] Tel Aviv Univ, Sackler Sch Med, Div Oncol, Meir Med Ctr,Genitourinary Oncol Serv, Kefar Sava, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5057
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5057
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Imaging response during therapy (tx) with radium-223 (Ra-223) for castrate resistant prostate cancer (CRPC) with bone metastases (BM)
    Keizman, Daniel
    Peer, Avivit
    Neumann, Avivit
    Rosenbaum, Eli
    Neiman, Victoria
    Gottfried, Maya
    Kuchuk, Iryna
    Sarid, David
    Gez, Eliahu
    Mermershtain, Wilmosh
    Rouvinov, Keren
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [2] Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases—analysis of an international multicenter database
    D Keizman
    M O Fosboel
    H Reichegger
    A Peer
    E Rosenbaum
    M-C Desax
    V Neiman
    P M Petersen
    J Mueller
    R Cathomas
    M Gottfried
    H Dresler
    D Sarid
    W Mermershtain
    K Rouvinov
    J Mortensen
    S Gillessen
    G Daugaard
    A Omlin
    Prostate Cancer and Prostatic Diseases, 2017, 20 : 289 - 293
  • [3] Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases-analysis of an international multicenter database
    Keizman, D.
    Fosboel, M. O.
    Reichegger, H.
    Peer, A.
    Rosenbaum, E.
    Desax, M-C
    Neiman, V.
    Petersen, P. M.
    Mueller, J.
    Cathomas, R.
    Gottfried, M.
    Dresler, H.
    Sarid, D.
    Mermershtain, W.
    Rouvinov, K.
    Mortensen, J.
    Gillessen, S.
    Daugaard, G.
    Omlin, A.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (03) : 289 - 293
  • [4] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [5] Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [6] Safety of cytotoxic chemotherapy following Radium-223 Chloride (Ra-223) therapy in the phase 3 alsympca study in patients with Castration-resistant Prostate Cancer (CRPC) with Bone Metastases
    Stroelin, P.
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    Tear, C. G. O'Bryan
    Staudacher, K.
    Vargas, J. E. Garcia
    Zou, J.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 60 - 60
  • [7] SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    O'Bryan-Tear, G.
    Staudacher, K.
    Garcia-Vargas, J. E.
    Zou, J.
    Parker, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 308 - 309
  • [8] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A-K
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [9] Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases
    Widmark, A.
    Helle, S. I.
    James, N.
    Larsson, A.
    Staudacher, K.
    Haugen, I.
    Garcia-Vargas, J.
    Nilsson, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S189 - S190
  • [10] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A. K.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 17 - 18
12345